drugset / Trial / NCT01656525
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-03
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gantenerumab | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | Gantenerumab | Monoclonal antibody | 105 mg | Subcutaneous |
| Subject | Gantenerumab | Monoclonal antibody | 225 mg | Subcutaneous |